ZIMBABWE – RBC Capital reiterated their outperform rating on shares of Biotie Therapies Oyj (NASDAQ:BITI) in a research report sent to investors on Monday morning, ARN reports. The brokerage currently has a $35.00 target price on the stock.
Several other analysts have also commented on BITI. Stifel Nicolaus began coverage on shares of Biotie Therapies Oyj in a report on Monday, July 6th. They issued a buy rating and a $30.00 target price for the company. Roth Capital assumed coverage on shares of Biotie Therapies Oyj in a research note on Tuesday, July 7th. They issued a buy rating and a $26.00 price target for the company. JMP Securities initiated coverage on shares of Biotie Therapies Oyj in a research note on Monday, July 6th. They set an outperform rating and a $32.00 target price for the company. Finally, Zacks cut shares of Biotie Therapies Oyj from a hold rating to a sell rating in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $30.75.
Biotie Therapies Oyj (NAZDAQ:BITI) traded up 2.97% on Monday, hitting $13.50. The stock had a trading volume of 9,249 shares. Biotie Therapies Oyj has a 12 month low of $12.75 and a 12 month high of $25.39. The stock’s market cap is $165.51 million. The firm’s 50 day moving average price is $16.61 and its 200-day moving average price is $18.11.
Biotie Therapies Oyj (NASDAQ:BITI) last released its earnings results on Thursday, August 20th. The company reported ($1.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by $0.67. On average, analysts forecast that Biotie Therapies Oyj will post ($2.87) EPS for the current year.
Biotie Therapies Oyj is a Finland-based biopharmaceutical company, which specializes in the field of neurodegenerative and psychiatric disorders. Its product portfolio comprises six drugs: Selincro (NAZDAQ:BITI), an orally administered opioid receptor ligand applied in the alcohol dependence therapy; Tozadenant (SYN115), a is an oral, potent and selective adenosine 2a (A2a) receptor antagonist for the Parkinson’s disease treatment; NRL-1, a intranasal formulation of diazepam for patients with epilepsy; Nepicastat (SYN117), an orally administered, potent and selective inhibitor of dopamine beta hydroxylase (DBH) for the cocaine dependence treatment; BTT-1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 (VAP-1) used in inflammation and fibrosis treatment; and SYN120, an oral, potent and dual antagonist of the 5-HT6 and 5HT2a receptors used in Alzheimer’s disease and other cognitive disorders, such as schizophrenia. It is a parent of Biotie Therapies GmbH, among others.
Receive News Ratings for Biotie Therapies Oyj Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biotie Therapies Oyj and related companies with MarketBeat.com’s FREE daily email newsletter.